Lilly Acquires Rights To TRPV-1 Receptor Antagonists From Glenmark
This article was originally published in PharmAsia News
Executive Summary
Eli Lilly is gaining a portfolio of molecules targeting the vanilloid-1 receptor, including Phase II candidate GRC 6211, through an agreement with Mumbai, India-based Glenmark Pharmaceuticals, announced Oct. 30
You may also be interested in...
Industry Talks Painful Reality Of Drug Development At NYAS Symposium
The 2013 Dr. Paul Janssen Awards honored UCSF’s David Julius for his work in pain, but both science and industry admits pain drug development is suffering due to the complexity and cost of the research.
Sanofi-Aventis Enters First R&D Pact In India For Glenmark's Pain Drugs; Instills Optimism In India's R&D Capabilities
MUMBAI - An extensive worldwide search for novel agents to treat chronic neuropathic pain has brought together Sanofi-Aventis and Indian drug maker Glenmark Pharma through a development and commercialization deal for transient receptor potential vanilloid (TRPV3) antagonist molecules
Sanofi-Aventis Enters First R&D Pact In India For Glenmark's Pain Drugs; Instills Optimism In India's R&D Capabilities
MUMBAI - An extensive worldwide search for novel agents to treat chronic neuropathic pain has brought together Sanofi-Aventis and Indian drug maker Glenmark Pharma through a development and commercialization deal for transient receptor potential vanilloid (TRPV3) antagonist molecules